[go: up one dir, main page]

NO20091321L - Menneskelige bindingsmolekyler i stand til a noytralisere influensavirus H5N1 og anvendelser derav - Google Patents

Menneskelige bindingsmolekyler i stand til a noytralisere influensavirus H5N1 og anvendelser derav

Info

Publication number
NO20091321L
NO20091321L NO20091321A NO20091321A NO20091321L NO 20091321 L NO20091321 L NO 20091321L NO 20091321 A NO20091321 A NO 20091321A NO 20091321 A NO20091321 A NO 20091321A NO 20091321 L NO20091321 L NO 20091321L
Authority
NO
Norway
Prior art keywords
antibodies
influenza virus
binding molecules
applications
molecules capable
Prior art date
Application number
NO20091321A
Other languages
English (en)
Inventor
Mark Throsby
Cornelis Adriaan De Kruif
Edward Norbert Van Den Brink
Original Assignee
Crucell Holland Bv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Crucell Holland Bv filed Critical Crucell Holland Bv
Publication of NO20091321L publication Critical patent/NO20091321L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses
    • C07K16/1018—Orthomyxoviridae, e.g. influenza virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/145—Orthomyxoviridae, e.g. influenza virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/10—Cells modified by introduction of foreign genetic material
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56983—Viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/00061—Methods of inactivation or attenuation
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16061—Methods of inactivation or attenuation
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16111—Influenzavirus A, i.e. influenza A virus
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/005—Assays involving biological materials from specific organisms or of a specific nature from viruses
    • G01N2333/08—RNA viruses
    • G01N2333/11—Orthomyxoviridae, e.g. influenza virus
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2469/00—Immunoassays for the detection of microorganisms
    • G01N2469/10—Detection of antigens from microorganism in sample from host

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • Pulmonology (AREA)
  • Biotechnology (AREA)
  • Biophysics (AREA)
  • Communicable Diseases (AREA)
  • Microbiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Engineering & Computer Science (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Cell Biology (AREA)
  • Physics & Mathematics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Food Science & Technology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Plant Pathology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)

Abstract

Den foreliggende oppfinnelsen relaterer seg til bindingsmolekyler slik som menneskelige monoklonale antistoffer som binder til influensavirus H5N1 og som har nøytraliserende aktivitet mot influensavirus H5N1. Beskrivelsen tilveiebringer nukleinsyremolekyler som koder for antistoffene, deres sekvenser og sammensetninger som innebefatter antistoffene og fremgangsmåtene for å identifisere eller produsere antistoffene. Antistoffene kan anvendes i diagnose, profylakse og/eller behandling av influensavirus H5N1-infeksjon. I en foretrukket utførelsesform, tilveiebringer antistoffene kryss-subtype beskyttelse in vivo. slik at infeksjoner med H5, H2, H6, H9 og Hl-baserte influensasubtyper kan forebygges og/eller behandles.
NO20091321A 2006-09-07 2009-03-31 Menneskelige bindingsmolekyler i stand til a noytralisere influensavirus H5N1 og anvendelser derav NO20091321L (no)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US84293006P 2006-09-07 2006-09-07
EP06120316 2006-09-07
EP06120644 2006-09-14
EP06125107 2006-11-30
EP07111235 2007-06-28
PCT/EP2007/059356 WO2008028946A2 (en) 2006-09-07 2007-09-06 Human binding molecules capable of neutralizing influenza virus h5n1 and uses thereof

Publications (1)

Publication Number Publication Date
NO20091321L true NO20091321L (no) 2009-03-31

Family

ID=39027173

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20091321A NO20091321L (no) 2006-09-07 2009-03-31 Menneskelige bindingsmolekyler i stand til a noytralisere influensavirus H5N1 og anvendelser derav

Country Status (15)

Country Link
US (5) US8192927B2 (no)
EP (2) EP2450377A1 (no)
JP (2) JP5161882B2 (no)
KR (1) KR101485197B1 (no)
AU (1) AU2007293662B2 (no)
CA (1) CA2663388C (no)
EA (1) EA017203B1 (no)
HR (1) HRP20130163T1 (no)
IL (2) IL197390A (no)
MX (1) MX2009002174A (no)
MY (1) MY170607A (no)
NO (1) NO20091321L (no)
PL (1) PL2059532T3 (no)
WO (1) WO2008028946A2 (no)
ZA (1) ZA200901171B (no)

Families Citing this family (156)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20160279239A1 (en) 2011-05-02 2016-09-29 Immunomedics, Inc. Subcutaneous administration of anti-cd74 antibody for systemic lupus erythematosus and autoimmune disease
USRE47770E1 (en) 2002-07-18 2019-12-17 Merus N.V. Recombinant production of mixtures of antibodies
CN105884893A (zh) 2002-07-18 2016-08-24 莫鲁斯有限公司 抗体混合物的重组生产
WO2004106375A1 (en) 2003-05-30 2004-12-09 Merus Biopharmaceuticals B.V. I.O. Fab library for the preparation of anti vegf and anti rabies virus fabs
US20100069614A1 (en) 2008-06-27 2010-03-18 Merus B.V. Antibody producing non-human mammals
CA2531684C (en) * 2003-07-22 2014-03-11 Crucell Holland B.V. Binding molecules against sars-coronavirus and uses thereof
CN102139106B (zh) 2004-05-27 2014-10-08 克鲁塞尔荷兰公司 能中和狂犬病病毒的结合分子及其应用
EP1799259B1 (en) * 2004-10-12 2012-12-05 Crucell Holland B.V. Binding molecules for the detection of cancer
US20160355591A1 (en) 2011-05-02 2016-12-08 Immunomedics, Inc. Subcutaneous anti-hla-dr monoclonal antibody for treatment of hematologic malignancies
US8052974B2 (en) 2005-05-12 2011-11-08 Crucell Holland B.V. Host cell specific binding molecules capable of neutralizing viruses and uses thereof
US8148085B2 (en) 2006-05-15 2012-04-03 Sea Lane Biotechnologies, Llc Donor specific antibody libraries
JP5574706B2 (ja) * 2006-06-06 2014-08-20 クルセル ホランド ベー ヴェー ブドウ球菌に対する殺活性を有するヒトの結合分子及びその使用方法
EA017203B1 (ru) 2006-09-07 2012-10-30 Круселл Холланд Б.В. Связывающие молекулы человека, способные нейтрализовать вирус гриппа h5n1, и их применение
EP2125886A2 (en) 2007-03-13 2009-12-02 Humabs LLC Antibodies against h5n1 strains of influenza a virus
CA2680237C (en) 2007-03-27 2018-11-06 Sea Lane Biotechnologies, Llc Constructs and libraries comprising antibody surrogate light chain sequences
US8542874B2 (en) * 2007-07-11 2013-09-24 Cairos Technologies Ag Videotracking
US8444986B2 (en) 2007-09-13 2013-05-21 Temasek Life Sciences Laboratory Limited Monoclonal antibodies specific to hemagglutinin from influenza virus H5-subtype and uses thereof
SG183031A1 (en) 2007-09-13 2012-08-30 Temasek Life Sciences Lab Ltd Monoclonal antibodies specific to hemagglutinin and neuraminidase from influenza virus h5-subtype or n1-subtype and uses thereof
EP3524619A1 (en) * 2007-12-06 2019-08-14 Dana-Farber Cancer Institute, Inc. Antibodies against influenza virus and methods of use thereof
ITTO20080204A1 (it) 2008-03-17 2009-09-18 Pomona Biotechnologies Llc Anticorpi monoclonali atti a reagire con una pluralita di sottotipi del virus influenzale a
EP2698380A1 (en) * 2008-03-28 2014-02-19 Sea Lane Biotechnologies, LLC Neutralizing molecules to viral antigens
ITTO20080398A1 (it) 2008-05-27 2009-11-28 Pomona Biotechnologies Llc Anticorpi monoclonali aventi proprieta' di cross-neutralizzazione omosubtipica per virus influenzali di tipo a sottotipo h1
RU2553325C2 (ru) * 2008-07-25 2015-06-10 Институт Фо Ресёч Ин Биомедицин Нейтрализующие антитела против вируса гриппа а и их использование
US8871207B2 (en) 2008-07-25 2014-10-28 Humabs, LLC Neutralizing anti-influenza A virus antibodies and uses thereof
GB0818356D0 (en) * 2008-10-07 2008-11-12 Istituto Superiore Di Sanito Antibodies
TWI381848B (zh) * 2008-10-20 2013-01-11 Imclone Llc 抗纖維母細胞生長因子受體-3 (fgfr-3) 抗體及包含其之醫藥組合物
NZ592036A (en) 2008-10-22 2012-12-21 Inst Research In Biomedicine Methods for producing antibodies from plasma cells
CN102438652B (zh) * 2008-11-12 2014-08-13 米迪缪尼有限公司 抗体制剂
CN102292350A (zh) 2008-12-24 2011-12-21 淡马锡生命科学研究院有限公司 对来自甲型流感病毒血凝素的融合肽特异的单克隆抗体及其用途
EP3009145A1 (en) 2009-03-30 2016-04-20 Mount Sinai School of Medicine of New York University Influenza virus vaccines and uses thereof
CA2760553A1 (en) * 2009-04-30 2010-11-04 Jr. James E. Crowe Monoclonal antibodies to influenza h1n1 virus and uses thereof
WO2010130636A1 (en) * 2009-05-11 2010-11-18 Crucell Holland B.V. Human binding molecules capable of neutralizing influenza virus h3n2 and uses thereof
US20120128671A1 (en) 2009-05-13 2012-05-24 Lawrence Horowitz Neutralizing molecules to influenza viruses
JP5941841B2 (ja) 2009-05-26 2016-06-29 アイカーン スクール オブ メディシン アット マウント サイナイ 周期的投与によって作製されたインフルエンザウイルスに対するモノクローナル抗体及びその使用
US8974788B2 (en) * 2009-08-14 2015-03-10 Theraclone Sciences, Inc. Compositions and methods for the therapy and diagnosis of influenza
EP2486054A4 (en) * 2009-10-09 2013-09-11 Univ Emory RECOMBINANT ANTIBODIES TO H1N1 INFLUENZA
JP6210685B2 (ja) * 2010-01-27 2017-10-11 マサチューセッツ インスティテュート オブ テクノロジー 標的化された広域スペクトルのインフルエンザ中和のための操作されたポリペプチド剤
CA2790380A1 (en) 2010-02-18 2011-08-25 Mount Sinai School Of Medicine Vaccines for use in the prophylaxis and treatment of influenza virus disease
EP2545074A4 (en) * 2010-03-08 2014-01-08 Celltrion Inc HUMAN MONOCLONAL ANTIBODIES MADE FROM HUMAN B-CELLS WITH NEUTRALIZING EFFECT AGAINST INFLUENZA A-VIRUS
MX2012011300A (es) 2010-03-30 2012-11-29 Sinai School Medicine Vacunas del virus de influenza y usos de las mismas.
CN102241768B (zh) * 2010-05-14 2013-12-25 中国科学院上海生命科学研究院 一种抗甲型h1n1流感病毒血凝素蛋白的抗体
CN106397584A (zh) * 2010-06-17 2017-02-15 特瑞利斯生物科学有限责任公司 可用于被动流感免疫的抗体
AU2011282423B2 (en) 2010-07-22 2015-05-14 Schrader, Sabariah Cross-protective pathogen protection, methods and compositions thereof
US8822663B2 (en) 2010-08-06 2014-09-02 Moderna Therapeutics, Inc. Engineered nucleic acids and methods of use thereof
EP2603237A4 (en) * 2010-08-12 2014-05-21 Theraclone Sciences Inc ANTI-HEMAGGLUTININE ANTIBODY COMPOSITIONS AND METHOD FOR THEIR USE
US9534042B2 (en) * 2010-09-03 2017-01-03 Fujita Health University Influenza virus-neutralizing antibody and screening method therefor
CA2811103C (en) 2010-09-14 2020-01-14 University Of Pittsburgh-Of The Commonwealth System Of Higher Education Computationally optimized broadly reactive antigens for influenza
RS63430B1 (sr) 2010-10-01 2022-08-31 Modernatx Inc Ribonukleinske kiseline koje sadrže n1-metil-pseudouracile i njihove primene
WO2012096994A2 (en) * 2011-01-10 2012-07-19 Emory University Antibodies directed against influenza
CA2827301A1 (en) * 2011-02-14 2012-08-23 Theraclone Sciences, Inc. Compositions and methods for the therapy and diagnosis of influenza
AU2012223358A1 (en) * 2011-03-01 2013-09-05 Amgen Inc. Sclerostin and DKK-1 bispecific binding agents
EP2691101A2 (en) 2011-03-31 2014-02-05 Moderna Therapeutics, Inc. Delivery and formulation of engineered nucleic acids
CA2831572C (en) * 2011-05-02 2019-11-26 Immunomedics, Inc. Ultrafiltration concentration of allotype selected antibodies for small-volume administration
AU2012273039B2 (en) 2011-06-20 2016-12-01 University Of Pittsburgh - Of The Commonwealth System Of Higher Education Computationally optimized broadly reactive antigens for H1N1 influenza
US8961978B2 (en) 2011-07-14 2015-02-24 Crucell Holland B.V. Human binding molecules capable of neutralizing influenza A viruses of phylogenetic group 1 and phylogenetic group 2 and influenza B viruses
MX352338B (es) 2011-07-18 2017-11-17 Inst Res Biomedicine Anticuerpos neutralizantes del virus de la influenza a y usos de estos.
WO2013016714A1 (en) 2011-07-28 2013-01-31 Sea Lane Biotechnologies Sur-binding proteins against erbb3
US20130084301A1 (en) * 2011-08-30 2013-04-04 Steven Foung Cluster of Neutralizing Antibodies to Hepatitis C Virus
GB201115214D0 (en) 2011-09-02 2011-10-19 Health Prot Agency Influenza virus antibody compositions
US9464124B2 (en) 2011-09-12 2016-10-11 Moderna Therapeutics, Inc. Engineered nucleic acids and methods of use thereof
AU2012312529B2 (en) 2011-09-20 2018-01-04 Icahn School Of Medicine At Mount Sinai Influenza virus vaccines and uses thereof
CA2791109C (en) 2011-09-26 2021-02-16 Merus B.V. Generation of binding molecules
DK3682905T3 (da) 2011-10-03 2022-02-28 Modernatx Inc Modificerede nukleosider, nukleotider og nukleinsyrer og anvendelser deraf
EP2768858B1 (en) 2011-10-18 2018-08-01 Emory University Antibodies directed against influenza
WO2013079473A1 (en) * 2011-11-28 2013-06-06 Crucell Holland B.V. Influenza virus vaccines and uses thereof
SG11201402780UA (en) 2011-12-02 2014-10-30 Aimm Therapeutics Bv Influenza a virus specific antibodies
CA2861515A1 (en) 2011-12-05 2013-06-13 Trellis Bioscience, Llc Antibodies useful in passive influenza immunization
KR101749316B1 (ko) 2011-12-15 2017-06-21 (주) 에이프로젠 Ｈ１ｎ１―감염된 환자들로부터 유도된 매우 잠재력 있는 넓은-스펙트럼 중화 단일클론 항체 및 이를 포함하는 바이러스의 치료용 조성물
DE12858350T1 (de) 2011-12-16 2021-10-07 Modernatx, Inc. Modifizierte mrna zusammensetzungen
US9975956B2 (en) 2011-12-22 2018-05-22 I2 Pharmaceuticals, Inc. Surrogate binding proteins which bind DR4 and/or DR5
BR112014018884A2 (pt) 2012-02-07 2017-07-04 Univ Pittsburgh Commonwealth Sys Higher Education antígenos amplamente reativos computacionalmente otimizados para viroses de influenza h3n2, h2n2, e b
MX359071B (es) 2012-02-13 2018-09-13 Univ Pittsburgh Commonwealth Sys Higher Education Antígenos ampliamente reactivos computacionalmente optimizados para influenza h5n1 humana y aviar.
US8834881B2 (en) 2012-03-08 2014-09-16 Crucell Holland B.V. Human binding molecules capable of binding to and neutralizing influenza B viruses and uses thereof
RU2639551C2 (ru) 2012-03-30 2017-12-21 Юниверсити Оф Питтсбург - Оф Зе Коммонвэлс Систем Оф Хайе Эдьюкейшн Оптимизированные с помощью вычислительных средств антигены с широким спектром реактивности для вирусов гриппа h5n1 и h1n1
US9878056B2 (en) 2012-04-02 2018-01-30 Modernatx, Inc. Modified polynucleotides for the production of cosmetic proteins and peptides
US9572897B2 (en) 2012-04-02 2017-02-21 Modernatx, Inc. Modified polynucleotides for the production of cytoplasmic and cytoskeletal proteins
HK1206601A1 (en) 2012-04-02 2016-01-15 Moderna Therapeutics, Inc. Modified polynucleotides for the production of biologics and proteins associated with human disease
US9283287B2 (en) 2012-04-02 2016-03-15 Moderna Therapeutics, Inc. Modified polynucleotides for the production of nuclear proteins
PT2838917T (pt) 2012-04-20 2019-09-12 Merus Nv Métodos e meios para a produção de moléculas similares a ig heterodiméricas
US9969794B2 (en) 2012-05-10 2018-05-15 Visterra, Inc. HA binding agents
EP2712626A1 (en) * 2012-09-28 2014-04-02 Fabentech Passive immunisation against influenza, in particular H5N1
BR112015010817A8 (pt) 2012-11-13 2018-01-23 Genentech Inc anticorpos anti-hemaglutinina isolado, método de tratamento, inibição ou prevenção de infecções, composição, composição farmacêutica, ácido nucleico isolado, célula hospedeira, método de produção de anticorpos e uso do anticorpo anti-hemaglutinina
HRP20220607T1 (hr) 2012-11-26 2022-06-24 Modernatx, Inc. Terminalno modificirana rna
SG11201503989PA (en) 2012-11-27 2015-06-29 Univ Pittsburgh Computationally optimized broadly reactive antigens for h1n1 influenza
CN105263516A (zh) 2012-12-18 2016-01-20 西奈山伊坎医学院 流感病毒疫苗及其用途
EP2970397A2 (en) 2013-03-14 2016-01-20 University Of Washington Through Its Center For Commercialization Polypeptides for treating and/or limiting influenza infection
JP6595448B2 (ja) 2013-03-14 2019-10-23 コントラフェクト コーポレイション 治療効率の増強のために鼻腔内送達する中和抗体に基づく組成物および方法
US9908930B2 (en) 2013-03-14 2018-03-06 Icahn School Of Medicine At Mount Sinai Antibodies against influenza virus hemagglutinin and uses thereof
US8980864B2 (en) 2013-03-15 2015-03-17 Moderna Therapeutics, Inc. Compositions and methods of altering cholesterol levels
US9650434B2 (en) 2013-04-02 2017-05-16 Xiamen University Broad-spectrum monoclonal antibody recognizing HA1 domain of hemagglutinin of influenza virus
MX369317B (es) 2013-05-30 2019-11-05 Janssen Vaccines & Prevention Bv Vacunas contra el virus de la influenza y sus usos.
EP3037819A4 (en) * 2013-08-23 2017-03-29 Fujita Health University Method of determining resistance to influenza virus
WO2015025900A1 (ja) 2013-08-23 2015-02-26 学校法人藤田学園 抗インフルエンザウイルス中和抗体
WO2015048744A2 (en) 2013-09-30 2015-04-02 Moderna Therapeutics, Inc. Polynucleotides encoding immune modulating polypeptides
RS60938B1 (sr) 2013-10-02 2020-11-30 Medimmune Llc Neutrališuća antitela na grip a i njihova upotreba
WO2015051214A1 (en) 2013-10-03 2015-04-09 Moderna Therapeutics, Inc. Polynucleotides encoding low density lipoprotein receptor
EP3070167A4 (en) * 2013-11-06 2017-06-07 Osaka University Antibody having broad neutralizing activity in group 1 influenza a virus
US10639370B2 (en) 2014-02-04 2020-05-05 Contrafect Corporation Antibodies useful in passive influenza immunization, and compositions, combinations and methods for use thereof
RU2720282C1 (ru) 2014-02-04 2020-04-28 Контрафект Корпорейшн Антитела, подходящие для пассивной иммунизации против гриппа, и их композиции, комбинации и способы применения
DK3105250T3 (da) 2014-02-10 2020-09-28 Igm Biosciences Inc Multispecifikke iga-bindingsmolekyler
AU2015231164B2 (en) 2014-03-19 2020-04-09 Dana-Farber Cancer Institute, Inc. Immunogenetic restriction on elicitation of antibodies
DK3134131T3 (en) 2014-04-23 2022-02-07 Modernatx Inc Nucleic acid vaccines
MX378904B (es) 2014-07-10 2025-03-10 Janssen Vaccines & Prevention Bv Vacunas para virus influenza y usos de las mismas.
SG11201610456UA (en) 2014-07-10 2017-01-27 Janssen Vaccines & Prevention Bv Influenza virus vaccines and uses thereof
WO2016011035A2 (en) 2014-07-15 2016-01-21 Medlmmune, Llc Neutralizing anti-influenza b antibodies and uses thereof
TWI702229B (zh) 2014-12-19 2020-08-21 美商再生元醫藥公司 流行性感冒病毒血球凝集素之人類抗體
CA2974699A1 (en) 2015-01-23 2016-07-28 Icahn School Of Medicine At Mount Sinai Influenza virus vaccination regimens
US10174127B2 (en) 2015-02-05 2019-01-08 Janssen Vaccines & Prevention B.V. Human neutralizing antibodies binding to influenza neuraminidase
EA038407B1 (ru) 2015-02-05 2021-08-24 Янссен Вэксинс Энд Превеншн Б.В. Связывающие молекулы, направленные против гемагглютинина вируса гриппа, и пути их применения
BR112017024206A2 (pt) 2015-05-11 2018-07-17 Janssen Vaccines & Prevention Bv compostos peptidomiméticos neutralizadores do vírus da gripe
PT3303384T (pt) 2015-06-01 2021-10-14 Medimmune Llc Moléculas de ligação neutralizantes anti-influenza e suas utilizações
WO2017083627A1 (en) 2015-11-13 2017-05-18 Visterra, Inc. Compositions and methods for treating and preventing influenza
IL304940A (en) 2016-01-13 2023-10-01 Medimmune Llc A method for treating type A influenza
CN109195629A (zh) 2016-02-24 2019-01-11 威特拉公司 流行性感冒抗体分子制剂
WO2017148889A1 (en) 2016-03-01 2017-09-08 Janssen Vaccines & Prevention B.V. Human neutralizing antibodies binding to influenza b neuraminidase
BR112018075032A2 (pt) 2016-06-15 2019-03-26 Icahn School Of Medicine At Mount Sinai proteínas de hemaglutinina do vírus influenza e seus uso
KR101835009B1 (ko) 2016-08-19 2018-03-07 주식회사 하이딥 터치 입력 장치
JP7265984B2 (ja) 2016-10-21 2023-04-27 アディマブ， エルエルシー 抗呼吸器合胞体ウイルス抗体、及び、それらの生成及び使用の方法
AU2017345759B2 (en) 2016-10-21 2024-06-20 Adimab, Llc Anti-respiratory syncytial virus antibodies, and methods of their generation and use
AU2017345786B2 (en) * 2016-10-21 2024-08-01 Adimab, Llc Anti-respiratory syncytial virus antibodies, and methods of their generation and use
US20200048308A1 (en) 2016-10-27 2020-02-13 Janssen Vaccines & Prevention B.V. Influenza virus neutralizing compounds
WO2018138681A1 (en) 2017-01-27 2018-08-02 National Research Council Of Canada Hemagglutinin-specific antibodies and uses thereof
US11040963B2 (en) 2017-02-02 2021-06-22 Janssen Vaccines & Prevention B.V. Piperazine derivatives for influenza virus inhibitions
WO2018141854A1 (en) 2017-02-02 2018-08-09 Janssen Vaccines & Prevention B.V. Piperazine derivatives for influenza virus inhibition
EP3579848B1 (en) 2017-02-08 2024-10-30 Dragonfly Therapeutics, Inc. Multi-specific binding proteins for activation of natural killer cells and therapeutic uses thereof to treat cancer
JP7685821B2 (ja) 2017-02-20 2025-05-30 ドラゴンフライ セラピューティクス， インコーポレイテッド Ｈｅｒ２、ＮＫＧ２ＤおよびＣＤ１６に結合するタンパク質
EP3606964A4 (en) 2017-04-03 2020-12-09 Immunomedics, Inc. SUBCUTANE ADMINISTRATION OF ANTIBODY DRUG CONJUGATES FOR CANCER THERAPY
US11254733B2 (en) 2017-04-07 2022-02-22 Icahn School Of Medicine At Mount Sinai Anti-influenza B virus neuraminidase antibodies and uses thereof
KR102119783B1 (ko) * 2017-08-14 2020-06-08 사회복지법인 삼성생명공익재단 인간 상피 성장 인자 수용체 변이체 ⅲ에 결합하는 항체 및 그의 항체 단편
JP7035170B2 (ja) 2017-09-15 2022-03-14 レンティジェン・テクノロジー・インコーポレイテッド 抗ｃｄ１９免疫療法によりがんを処置するための組成物および方法
BR112020014343A2 (pt) 2018-01-23 2020-12-08 Janssen Vaccines & Prevention B.V. Vacinas contra o vírus da influenza e seus usos
US11780907B2 (en) 2018-01-26 2023-10-10 Regeneron Pharmaceuticals, Inc. Human antibodies to influenza hemagglutinin
MX2020008336A (es) 2018-02-08 2020-09-21 Dragonfly Therapeutics Inc Dominios variables de anticuerpos que se dirigen al receptor nkg2d.
BR112020015994A2 (pt) 2018-02-08 2020-12-15 Dragonfly Therapeutics, Inc. Terapia de combinação do câncer que envolve proteínas de ligação multiespecíficas que ativam células natural killer
JP7353576B2 (ja) 2018-02-20 2023-10-02 ドラゴンフライ セラピューティクス， インコーポレイテッド Ｃｄ３３、ｎｋｇ２ｄ、及びｃｄ１６に結合する多重特異性結合タンパク質、ならびにその使用方法
US12364746B2 (en) 2018-06-21 2025-07-22 Icahn School Of Medicine At Mount Sinai Mosaic influenza virus hemagglutinin polypeptides and uses thereof
EA202091888A1 (ru) 2018-08-08 2020-10-23 Драгонфлай Терапьютикс, Инк. Вариабельные домены антител, нацеленные на рецептор nkg2d
EA202190468A1 (ru) 2018-08-08 2021-07-06 Драгонфлай Терапьютикс, Инк. Мультиспецифические связывающие белки, которые связывают bcma, nkg2d и cd16, и способы их применения
SG11202101298XA (en) 2018-08-08 2021-03-30 Dragonfly Therapeutics Inc Proteins binding nkg2d, cd16 and a tumor-associated antigen
CN111057718A (zh) * 2018-10-17 2020-04-24 南京大学 一种稳定表达绿色荧光蛋白的egfp-sp2/0细胞株及其构建方法
KR102113302B1 (ko) * 2018-12-24 2020-05-20 원광대학교산학협력단 상보성결정부 기반 조류 인플루엔자 바이러스의 h5 아형에 특이적으로 결합하는 펩티드 및 이의 용도
CA3132521A1 (en) 2019-03-25 2020-10-01 Visterra, Inc. Compositions and methods for treating and preventing influenza
AU2020342463A1 (en) 2019-09-05 2022-03-24 Janssen Vaccines & Prevention B.V. Influenza virus vaccines and uses thereof
WO2021173965A1 (en) 2020-02-28 2021-09-02 Massachusetts Institute Of Technology Identification of variable influenza residues and uses thereof
CN111440228B (zh) * 2020-03-09 2021-08-24 扬州大学 多种亚型流感病毒ha2蛋白共同抗原表位、抗体、鉴定方法和应用
WO2021201677A1 (en) 2020-04-01 2021-10-07 Kiadis Pharma Intellectual Property B.V. Compositions and methods targeting influenza
US20210325367A1 (en) * 2020-04-20 2021-10-21 Satish Mahna Controlled Exposure to Pathogens for Generating Immunity
AR122018A1 (es) 2020-05-06 2022-08-03 Dragonfly Therapeutics Inc Proteínas que se unen a nkg2d, cd16 y clec12a
CN116761605A (zh) * 2021-02-04 2023-09-15 四川海思科制药有限公司 Ha抑制剂化合物的盐及晶型
CN117222663A (zh) 2021-03-03 2023-12-12 蜻蜓疗法股份有限公司 使用结合nkg2d、cd16和肿瘤相关抗原的多特异性结合蛋白治疗癌症的方法
TW202309075A (zh) * 2021-04-30 2023-03-01 美商亞得捷歐治療公司 對冠狀病毒s蛋白質具特異性之化合物及其用途
WO2024104947A2 (en) 2022-11-14 2024-05-23 Janssen Vaccines & Prevention B.V. Influenza b virus vaccines and uses thereof
WO2025019631A1 (en) 2023-07-19 2025-01-23 Icahn School Of Medicine At Mount Sinai Immunogenic compositions containing inactivated influenza a virus and cpg oligonucleotide adjuvant and uses thereof
TW202527960A (zh) 2023-09-06 2025-07-16 美商賽諾菲巴斯德公司 經修飾ｂ型流感血球凝集素多肽及核酸及其用途
WO2025090499A1 (en) * 2023-10-24 2025-05-01 University Of Pittsburgh - Of The Commonwealth System Of Higher Education Monoclonal antibodies that bind an antigen of epithelial ovarian cancer and their use
WO2025149667A1 (en) 2024-01-12 2025-07-17 Pheon Therapeutics Ltd Antibody drug conjugates and uses thereof

Family Cites Families (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ZA836080B (en) * 1982-08-23 1984-04-25 Scripps Clinic Res Broad spectrum influenza antisera
US4625015A (en) * 1982-08-23 1986-11-25 Scripps Clinic & Research Foundation Broad spectrum influenza antisera
NZ207394A (en) 1983-03-08 1987-03-06 Commw Serum Lab Commission Detecting or determining sequence of amino acids
NL9101953A (nl) 1991-11-21 1993-06-16 Seed Capital Investments Testinrichting omvattende een plaat met een veelvoud van putjes met een bijbehorende doseerinrichting, alsmede een kit die deze inrichtingen omvat en toepassing van de inrichtingen.
US5589174A (en) * 1992-09-17 1996-12-31 Takara Shuzo Co., Ltd. Anti-human influenza virus antibody
JP3037554B2 (ja) * 1993-04-20 2000-04-24 寳酒造株式会社 免疫原性人工ポリペプチド
JP3061960B2 (ja) * 1992-09-17 2000-07-10 寳酒造株式会社 抗ヒトインフルエンザウイルス抗体
US5624949A (en) 1993-12-07 1997-04-29 Eli Lilly And Company Protein kinase C inhibitors
JP3584990B2 (ja) * 1994-05-09 2004-11-04 タカラバイオ株式会社 抗ヒトインフルエンザウイルス抗体
US6265150B1 (en) 1995-06-07 2001-07-24 Becton Dickinson & Company Phage antibodies
ATE230850T1 (de) 1996-10-08 2003-01-15 Bisys B V U Verfahren und mittel zur auswahl von peptiden und proteinen mit spezifischer affinität zu einem zielmolekül
US20030161813A1 (en) 1998-04-30 2003-08-28 Ton Logtenberg Altering the properties of cells or of particles with membranes derived from cells by means of lipid-modified proteinaceous molecules
US6440736B1 (en) 1998-10-16 2002-08-27 U-Bisys B.V. Altering the properties of cells or of particles with membranes derived from cells by means of lipid-modified proteinaceous molecules
US7091324B2 (en) * 1998-11-05 2006-08-15 Board Of Trustees Of Leland Stanford Junior University Prevention and treatment of HCV infection employing antibodies directed against conformational epitopes
CA2370477C (en) 1999-04-15 2010-06-29 Crucell Holland B.V. Recombinant protein production in a human cell using sequences encoding adenovirus e1 protein
US7521220B2 (en) 1999-11-26 2009-04-21 Crucell Holland B.V. Production of vaccines
EP1224943A1 (en) 2001-01-19 2002-07-24 Crucell Holland B.V. Fibronectin as a tumor marker detected by phage antibodies
CA2449071C (en) 2001-06-15 2008-12-16 Crucell Holland B.V. Chimaeric phages
US7070926B2 (en) 2001-06-15 2006-07-04 Crucell Holland B.V. Chimaeric phages
JP2005535572A (ja) * 2002-04-12 2005-11-24 メディミューン，インコーポレーテッド 組換え抗インターロイキン−９抗体
US20100069614A1 (en) 2008-06-27 2010-03-18 Merus B.V. Antibody producing non-human mammals
WO2005012337A2 (en) 2003-07-15 2005-02-10 Crucell Holland B.V. Antigenic peptides of sars coronavirus and uses thereof
CA2531684C (en) 2003-07-22 2014-03-11 Crucell Holland B.V. Binding molecules against sars-coronavirus and uses thereof
WO2005063819A2 (en) 2003-12-23 2005-07-14 Crucell Holland B.V. Human binding molecule against cd1a
US20070287163A1 (en) 2004-05-17 2007-12-13 Crucell Holland B.V. Methods for Diagnosis of Acute Myeloid Leukemia
CN102139106B (zh) 2004-05-27 2014-10-08 克鲁塞尔荷兰公司 能中和狂犬病病毒的结合分子及其应用
EP1799259B1 (en) 2004-10-12 2012-12-05 Crucell Holland B.V. Binding molecules for the detection of cancer
NZ553701A (en) 2004-11-11 2009-12-24 Crucell Holland Bv Composition comprising SC03-014 and SC03-022 antibodies against SARS-CoV
CA2591665C (en) 2004-12-20 2015-05-05 Crucell Holland B.V. Binding molecules capable of neutralizing west nile virus and uses thereof
JP4580338B2 (ja) 2004-12-23 2010-11-10 エーエスエムエル ネザーランズ ビー．ブイ． リソグラフィ装置、エキシマ・レーザ、およびデバイス製造方法
US8052974B2 (en) 2005-05-12 2011-11-08 Crucell Holland B.V. Host cell specific binding molecules capable of neutralizing viruses and uses thereof
JP4758148B2 (ja) * 2005-06-14 2011-08-24 泰三 宇田 インフルエンザウイルスのヘマグルチニンに対する抗体酵素
US20090130652A1 (en) 2005-06-23 2009-05-21 Crucell Holland B.V. Optimization of West Nile Virus Antibodies
CN101228267B (zh) 2005-07-22 2013-01-23 克鲁塞尔荷兰公司 生产冠状病毒的细胞系
WO2007031550A2 (en) 2005-09-15 2007-03-22 Crucell Holland B.V. Method for preparing immunoglobulin libraries
KR20200058579A (ko) 2006-06-06 2020-05-27 얀센 백신스 앤드 프리벤션 비.브이. 장내구균에 대한 사멸활성을 갖는 인간결합분자 및 그것의 용도
JP5574706B2 (ja) 2006-06-06 2014-08-20 クルセル ホランド ベー ヴェー ブドウ球菌に対する殺活性を有するヒトの結合分子及びその使用方法
EA017203B1 (ru) 2006-09-07 2012-10-30 Круселл Холланд Б.В. Связывающие молекулы человека, способные нейтрализовать вирус гриппа h5n1, и их применение
WO2009083009A2 (en) 2008-01-03 2009-07-09 Genmab A/S Monoclonal antibodies against cd32b
US8148797B2 (en) 2008-06-26 2012-04-03 Taiwan Semiconductor Manufacturing Co., Ltd. Chip pad resistant to antenna effect and method
WO2010130636A1 (en) 2009-05-11 2010-11-18 Crucell Holland B.V. Human binding molecules capable of neutralizing influenza virus h3n2 and uses thereof
CA2791109C (en) 2011-09-26 2021-02-16 Merus B.V. Generation of binding molecules
PT2838917T (pt) 2012-04-20 2019-09-12 Merus Nv Métodos e meios para a produção de moléculas similares a ig heterodiméricas

Also Published As

Publication number Publication date
MY170607A (en) 2019-08-20
US20140065156A1 (en) 2014-03-06
US10005831B2 (en) 2018-06-26
US8192927B2 (en) 2012-06-05
JP2012245003A (ja) 2012-12-13
JP5161882B2 (ja) 2013-03-13
KR20090059121A (ko) 2009-06-10
IL249291B (en) 2018-11-29
IL197390A0 (en) 2011-08-01
HRP20130163T1 (hr) 2013-03-31
EA017203B1 (ru) 2012-10-30
EA200970255A1 (ru) 2009-10-30
US20120276115A1 (en) 2012-11-01
JP5701827B2 (ja) 2015-04-15
AU2007293662A1 (en) 2008-03-13
KR101485197B1 (ko) 2015-01-23
CA2663388A1 (en) 2008-03-13
JP2010502207A (ja) 2010-01-28
AU2007293662B2 (en) 2012-10-04
PL2059532T3 (pl) 2013-05-31
EP2059532A2 (en) 2009-05-20
US20160024188A1 (en) 2016-01-28
IL197390A (en) 2017-11-30
US20090311265A1 (en) 2009-12-17
CA2663388C (en) 2017-01-17
HK1126799A1 (en) 2009-09-11
EP2059532B1 (en) 2012-12-26
ZA200901171B (en) 2010-02-24
US8691223B2 (en) 2014-04-08
EP2450377A1 (en) 2012-05-09
MX2009002174A (es) 2009-03-12
WO2008028946A3 (en) 2008-10-16
IL249291A0 (en) 2017-01-31
WO2008028946A2 (en) 2008-03-13
US20120093823A1 (en) 2012-04-19
US9011848B2 (en) 2015-04-21
US9109017B2 (en) 2015-08-18

Similar Documents

Publication Publication Date Title
NO20091321L (no) Menneskelige bindingsmolekyler i stand til a noytralisere influensavirus H5N1 og anvendelser derav
MY183517A (en) Human binding molecules capable of neutralizing influenza virus h3n2 and uses thereof
EA200870594A1 (ru) Связывающие человеческие молекулы с киллерной активностью в отношении энтерококков и их применение
PH12015502553A1 (en) Human binding molecules capable of binding to and neutralizing influenza b viruses and uses thereof
PH12013502479A1 (en) Human binding molecules capable of neutralizing influenza a viruses of phylogenetic group 1 and phylogenetic group 2 and influenza b viruses
EA201201650A1 (ru) Связывающие молекулы человека, имеющие убивающую активность против стафилококков, и их применения
BR112014032316A2 (pt) proteínas de repetição de anquirina projetadas que se ligam ao fator de crescimento derivado de plaqueta
EA201001639A1 (ru) Композиции и способы их получения и применения
MX2018009945A (es) Composiciones y metodos novedosos para el tratamiento de las enfermedades relacionadas con la inmunidad.
EA200970581A1 (ru) Кристаллическое твёрдое основание разагилина
EA201190217A1 (ru) Замещенные 2-ацетамидо-5-арил-1,2,4-триазолоны и их применение
BR112013032434A2 (pt) restauração dentária, método para sua produção e vidro cerâmico
UY34701A (es) Formas sólidas de un profármaco de nucleótidos de tiofosforamidato
BR112013020259A2 (pt) tratamento de osteoartrite e dores
DE602008004317D1 (de) Verbindungen zur behandlung von hepatitis c
EA201000391A1 (ru) Соединение, представляющее собой ингибитор гликогенфосфорилазы, и его фармацевтическая композиция
WO2010135521A3 (en) Compositions and methods for the therapy and diagnosis of influenza
CL2011003002A1 (es) Anticuerpo monoclonal o un fragmento del mismo que se une a la proteina m2-1 del virus respiratorio sincicial (vrs) humano; secuencias nucleotidicas; composicion farmaceutica; metodo de diagnostico de infeccion producida por vrs; kit; y uso de dicho anticuerpo para preparar un medicamento.
MX382563B (es) Formas cristalinas de bilastina y procedimientos para su preparacion.
EA201001835A1 (ru) Противовирусные соли
WO2011103028A3 (en) Compositions and methods for inhibiting mmset
MY165458A (en) Human binding molecules capable of neutralizing influenza virus h5n1 and uses thereof
EA201200182A1 (ru) Связывающие человеческие молекулы с киллерной активностью в отношении энтерококков и их применение
EA201100080A1 (ru) Фенантреноновые соединения, композиции и способы
CY1114939T1 (el) Ανθρωπινα μορια προσδεσης ικανα να εξουδετερωσουν τον ιο της γριπης η5ν1 και χρησεις αυτων

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application